Silence Therapeutics plc
SLN
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNAā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.37
Price+2.25%
$0.14
1Y
Price
Market Cap
$300.880m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-13082.4%
EBITDA Margin-13181.1%
Net Profit Margin-6851.6%
Free Cash Flow MarginRevenue
$24.853m
-42.5%
1y CAGR+15.0%
3y CAGR+29.9%
5y CAGREarnings
-$62.668m
-38.3%
1y CAGR-9.7%
3y CAGR-14.2%
5y CAGREPS
-$3.96
-67.1%
1y CAGR-8.8%
3y CAGR-51.7%
5y CAGRBook Value
$74.063m
$146.790m
Assets$72.727m
Liabilities$182k
DebtDebt to Assets
0.1%
-
Debt to EBITDAFree Cash Flow
-$69.959m
-3.1%
1y CAGR-14.6%
3y CAGR-230.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company